Status:
COMPLETED
Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This study will establish that the MK0431 100 mg anhydrous formulation tablets are bioequivalent to the MK0431 100 mg monohydrate final market image (FMI) tablets.
Eligibility Criteria
Inclusion
- Subject is in good health
- Female subjects must have a negative pregnancy test
- Subject is within 30% of ideal body weight
- Subject does not smoke
- Subject agrees to follow the study guidelines
Exclusion
- Subject has a history of any illness that might confound the results of the study or make participation unsafe for the subject
- Subject has a history of hypoglycemia
- Subject has a history of any hepatic disease
- Subject is taking any oral, parenteral, topical or implantable contraceptives
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2004
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00944450
Start Date
August 1 2004
End Date
November 1 2004
Last Update
August 19 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.